Treatment Approach for cT3N1M0 Invasive Ductal Carcinoma of the Breast

Initial Workup and Staging

The National Comprehensive Cancer Network recommends a complete clinical evaluation including physical examination, bilateral mammography, and breast ultrasound to accurately assess the extent of disease in patients with clinical stage T3N1M0 invasive ductal carcinoma of the breast 3
Pathologic diagnosis with core needle biopsy should be obtained to determine tumor characteristics including ER/PR receptor status and HER2 status in patients with clinical stage T3N1M0 invasive ductal carcinoma of the breast 3
Additional imaging studies such as chest imaging and liver function tests are recommended, while bone scan and abdominal imaging are optional unless directed by symptoms in patients with clinical stage T3N1M0 invasive ductal carcinoma of the breast 3
PET or PET/CT scans are generally discouraged for evaluating stage III disease except when other staging studies are equivocal or suspicious (category 2B) in patients with clinical stage T3N1M0 invasive ductal carcinoma of the breast 3

For operable locally advanced disease (T3N1M0), surgical options include mastectomy with level I/II axillary lymph node dissection, with or without delayed breast reconstruction, as recommended by the National Comprehensive Cancer Network 1, 4
Breast-conserving surgery (lumpectomy) with level I/II axillary dissection is recommended if negative margins can be achieved, as stated by the National Comprehensive Cancer Network 1, 4
Sentinel lymph node biopsy is recommended in the surgical staging of the clinically negative axilla, according to the National Comprehensive Cancer Network and Annals of Oncology 4, 5

Postoperative radiotherapy is strongly recommended after breast-conserving surgery, as stated by the National Comprehensive Cancer Network and Annals of Oncology 4, 5
For patients with T3N1M0 disease, radiation to the chest wall and supraclavicular lymph nodes is recommended after mastectomy, according to the National Comprehensive Cancer Network and Annals of Oncology 4, 6
Strong consideration should be given to including the internal mammary lymph nodes in the radiation field (category 2B), as recommended by the National Comprehensive Cancer Network 4

Neoadjuvant chemotherapy may be considered to potentially downsize the tumor and increase the likelihood of breast conservation, as stated by the National Comprehensive Cancer Network 4, 7
For HER2-positive tumors, an anthracycline-based chemotherapy regimen incorporating trastuzumab is recommended, according to the National Comprehensive Cancer Network 1
For hormone receptor-positive disease, endocrine therapy is recommended following completion of chemotherapy, as stated by the National Comprehensive Cancer Network 1, 4
For HER2-positive disease, complete up to one year of trastuzumab therapy (category 1), as recommended by the National Comprehensive Cancer Network 4

Failing to perform a complete preoperative assessment of tumor characteristics (ER/PR, HER2 status) which are crucial for treatment planning, as stated by the National Comprehensive Cancer Network 3
Omitting radiation therapy after breast-conserving surgery, which significantly increases the risk of local recurrence, according to the National Comprehensive Cancer Network and Annals of Oncology 4, 5
Not completing the full course of adjuvant systemic therapy, which may compromise long-term outcomes, as stated by the National Comprehensive Cancer Network 4
Overlooking the need for post-mastectomy radiation in patients with T3N1M0 disease, which reduces local recurrence risk, according to the National Comprehensive Cancer Network and Annals of Oncology 4, 6

Bone health should be monitored in patients receiving aromatase inhibitors as part of endocrine therapy, as recommended by the Journal of Clinical Oncology 9